vepdegestrant News

FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer

FDA · estrogen receptor-positive, HER2-negative breast cancer · 6 min

Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer

FDA · Oncology - Advanced Breast Cancer · 3 min

FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant

FDA · advanced or metastatic HR-positive, HER2-negative breast cancer · 13 min

Arvinas Receives FDA Approval for VEPPANU (Vepdegestrant), First PROTAC Drug for ESR1-Mutated Breast Cancer

FDA · Oncology - Breast Cancer · 3 min